Published in Clin Infect Dis on January 25, 2007
Soluble markers of inflammation and coagulation but not T-cell activation predict non-AIDS-defining morbid events during suppressive antiretroviral treatment. J Infect Dis (2014) 3.66
Incomplete reconstitution of T cell subsets on combination antiretroviral therapy in the AIDS Clinical Trials Group protocol 384. Clin Infect Dis (2009) 3.39
Potential risks and benefits of HIV treatment simplification: a simulation model of a proposed clinical trial. Clin Infect Dis (2007) 1.57
Antiretroviral treatment of US children with perinatally acquired HIV infection: temporal changes in therapy between 1991 and 2009 and predictors of immunologic and virologic outcomes. J Acquir Immune Defic Syndr (2011) 1.55
Long-term increase in CD4+ T-cell counts during combination antiretroviral therapy for HIV-1 infection. AIDS (2010) 1.54
Continuous improvement in the immune system of HIV-infected children on prolonged antiretroviral therapy. AIDS (2008) 1.13
Long-term CD4+ lymphocyte response following HAART initiation in a U.S. Military prospective cohort. AIDS Res Ther (2011) 1.11
A randomized, placebo controlled, double masked phase IB study evaluating the safety and antiviral activity of aprepitant, a neurokinin-1 receptor antagonist in HIV-1 infected adults. PLoS One (2011) 1.00
Poor baseline immune function predicts an incomplete immune response to combination antiretroviral treatment despite sustained viral suppression. J Acquir Immune Defic Syndr (2009) 0.92
Replication capacity in relation to immunologic and virologic outcomes in HIV-1-infected treatment-naive subjects. J Acquir Immune Defic Syndr (2009) 0.85
Highly efficient neutralization by plasma antibodies from human immunodeficiency virus type-1 infected individuals on antiretroviral drug therapy. J Clin Immunol (2014) 0.76
Immunological function restoration with lopinavir/ritonavir versus efavirenz containing regimens in HIV-infected patients: a randomized clinical trial. AIDS Res Hum Retroviruses (2014) 0.76
Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med (2011) 69.36
Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep (2009) 11.30
Retention in care: a challenge to survival with HIV infection. Clin Infect Dis (2007) 10.66
Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA (2012) 8.94
Antiretroviral therapy in a thousand patients with AIDS in Haiti. N Engl J Med (2005) 8.13
Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc Natl Acad Sci U S A (2008) 6.70
Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy. AIDS (2005) 5.08
ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia. PLoS Pathog (2007) 4.82
AIDS. Promote HIV chemoprophylaxis research, don't prevent it. Science (2005) 4.44
Integrated Modeling Program, Applied Chemical Theory (IMPACT). J Comput Chem (2005) 3.71
Current consensus guidelines for treatment of neurocysticercosis. Clin Microbiol Rev (2002) 3.37
CCL3L1-CCR5 genotype influences durability of immune recovery during antiretroviral therapy of HIV-1-infected individuals. Nat Med (2008) 2.94
Loss of bone mineral density after antiretroviral therapy initiation, independent of antiretroviral regimen. J Acquir Immune Defic Syndr (2009) 2.75
Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine. J Infect Dis (2003) 2.68
Patients referred to an urban HIV clinic frequently fail to establish care: factors predicting failure. AIDS Care (2005) 2.64
Antiretroviral durability and tolerability in HIV-infected adults living in urban Kenya. J Acquir Immune Defic Syndr (2007) 2.61
Successful cardiac transplantation in an HIV-1-infected patient with advanced disease. N Engl J Med (2003) 2.56
Inflammation and mortality in HIV-infected adults: analysis of the FRAM study cohort. J Acquir Immune Defic Syndr (2010) 2.47
The study of fat redistribution and metabolic change in HIV infection (FRAM): methods, design, and sample characteristics. Am J Epidemiol (2006) 2.44
The role of immune reconstitution inflammatory syndrome in AIDS-related Cryptococcus neoformans disease in the era of highly active antiretroviral therapy. Clin Infect Dis (2005) 2.43
Factors associated with the use of highly active antiretroviral therapy in patients newly entering care in an urban clinic. J Acquir Immune Defic Syndr (2003) 2.33
High frequency of clinically significant mutations after first-line generic highly active antiretroviral therapy failure: implications for second-line options in resource-limited settings. Clin Infect Dis (2009) 2.17
Neurocysticercosis: A natural human model of epileptogenesis. Epilepsia (2014) 2.11
New concepts in the diagnosis and management of neurocysticercosis (Taenia solium). Am J Trop Med Hyg (2005) 2.10
Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4+ cell infection. PLoS One (2010) 2.09
Decreased adherence to antiretroviral therapy observed prior to transient human immunodeficiency virus type 1 viremia. J Infect Dis (2007) 2.06
Neuroendoscopic diagnosis of central nervous system histoplasmosis with basilar arachnoiditis. World Neurosurg (2011) 2.05
An updated review on Cryptosporidium and Giardia. Gastroenterol Clin North Am (2006) 2.05
Effects of bacterial vaginosis and other genital infections on the natural history of human papillomavirus infection in HIV-1-infected and high-risk HIV-1-uninfected women. J Infect Dis (2005) 2.04
Limited immune restoration after 3 years' suppression of HIV-1 replication in patients with moderately advanced disease. AIDS (2002) 2.02
Serum immune activation markers are persistently increased in patients with HIV infection after 6 years of antiretroviral therapy despite suppression of viral replication and reconstitution of CD4+ T cells. J Infect Dis (2009) 1.95
Neurocysticercosis: neglected but not forgotten. PLoS Negl Trop Dis (2012) 1.95
Majority of CD4+ T cells from peripheral blood of HIV-1-infected individuals contain only one HIV DNA molecule. Proc Natl Acad Sci U S A (2011) 1.93
The production of reactive oxygen species by complex I. Biochem Soc Trans (2008) 1.87
Late diagnosis of HIV infection: the role of age and sex. Am J Med (2007) 1.86
The tablet formulation of lopinavir/ritonavir provides similar bioavailability to the soft-gelatin capsule formulation with less pharmacokinetic variability and diminished food effect. J Acquir Immune Defic Syndr (2007) 1.84
Bone mineral density in HIV-negative men participating in a tenofovir pre-exposure prophylaxis randomized clinical trial in San Francisco. PLoS One (2011) 1.84
Genotypic and phenotypic characterization of HIV-1 isolates obtained from patients on rilpivirine therapy experiencing virologic failure in the phase 3 ECHO and THRIVE studies: 48-week analysis. J Acquir Immune Defic Syndr (2012) 1.84
Discovery of Potent and Selective Inhibitors of Calcium-Dependent Protein Kinase 1 (CDPK1) from C. parvum and T. gondii. ACS Med Chem Lett (2010) 1.82
A once-daily lopinavir/ritonavir-based regimen provides noninferior antiviral activity compared with a twice-daily regimen. J Acquir Immune Defic Syndr (2006) 1.76
Long-term safety and durable antiretroviral activity of lopinavir/ritonavir in treatment-naive patients: 4 year follow-up study. AIDS (2004) 1.74
Predictive accuracy of the Veterans Aging Cohort Study index for mortality with HIV infection: a North American cross cohort analysis. J Acquir Immune Defic Syndr (2013) 1.72
Administration of protein-conjugate pneumococcal vaccine to patients who have invasive disease after splenectomy despite their having received 23-valent pneumococcal polysaccharide vaccine. J Infect Dis (2005) 1.72
"White coat compliance" limits the reliability of therapeutic drug monitoring in HIV-1-infected patients. HIV Clin Trials (2008) 1.68
Ivermectin versus albendazole or thiabendazole for Strongyloides stercoralis infection. Cochrane Database Syst Rev (2016) 1.66
Risk factor analyses for immune reconstitution inflammatory syndrome in a randomized study of early vs. deferred ART during an opportunistic infection. PLoS One (2010) 1.62
Analysis of the virological response with respect to baseline viral phenotype and genotype in protease inhibitor-experienced HIV-1-infected patients receiving lopinavir/ritonavir therapy. Antivir Ther (2002) 1.61
Relative replication capacity and selective advantage profiles of protease inhibitor-resistant hepatitis C virus (HCV) NS3 protease mutants in the HCV genotype 1b replicon system. Antimicrob Agents Chemother (2007) 1.59
Randomized trial of clinical safety of daily oral tenofovir disoproxil fumarate among HIV-uninfected men who have sex with men in the United States. J Acquir Immune Defic Syndr (2013) 1.57
Clinical validation of the NeuroScreen. J Neurovirol (2005) 1.57
Effect of pulmonary tuberculosis on mortality in patients receiving HAART. AIDS (2009) 1.56
HIV antigens can induce TGF-beta(1)-producing immunoregulatory CD8+ T cells. J Immunol (2002) 1.55
Impact of hepatitis B virus infection on human immunodeficiency virus response to antiretroviral therapy in Nigeria. Clin Infect Dis (2009) 1.52
Sexual risk behavior among HIV-uninfected men who have sex with men participating in a tenofovir preexposure prophylaxis randomized trial in the United States. J Acquir Immune Defic Syndr (2013) 1.50
A once-daily lopinavir/ritonavir-based regimen is noninferior to twice-daily dosing and results in similar safety and tolerability in antiretroviral-naive subjects through 48 weeks. J Acquir Immune Defic Syndr (2009) 1.49
A positive enzyme-linked immunoelectrotransfer blot assay result for a patient without evidence of cysticercosis. Clin Infect Dis (2002) 1.49
Intrathecal mafosfamide: a preclinical pharmacology and phase I trial. J Clin Oncol (2005) 1.48
Once-daily versus twice-daily lopinavir/ritonavir in antiretroviral-naive HIV-positive patients: a 48-week randomized clinical trial. J Infect Dis (2004) 1.48
No evidence for decay of the latent reservoir in HIV-1-infected patients receiving intensive enfuvirtide-containing antiretroviral therapy. J Infect Dis (2010) 1.45
The marriage of science and optimized HIV care in resource-limited settings. AIDS (2008) 1.44
Transmitted antiretroviral drug resistance among acute and recent HIV infections in North Carolina from 1998 to 2007. Antivir Ther (2009) 1.42
When to begin highly active antiretroviral therapy? Evidence supporting initiation of therapy at CD4+ lymphocyte counts <350 cells/microL. Clin Infect Dis (2003) 1.42
Whole-blood interleukin-18 level during early HIV-1 infection is associated with reduced CXCR4 coreceptor expression and interferon- gamma levels. J Infect Dis (2007) 1.42
Opt-out screening for Chlamydia trachomatis and Neisseria gonorrhoeae in female detainees at Cook County jail in Chicago, IL. Sex Transm Dis (2014) 1.41
Contemporary neurosurgical approaches to neurocysticercosis. Am J Trop Med Hyg (2009) 1.41
Effects of growth hormone on abnormal visceral adipose tissue accumulation and dyslipidemia in HIV-infected patients. J Acquir Immune Defic Syndr (2004) 1.39
Antiviral activity and safety of 873140, a novel CCR5 antagonist, during short-term monotherapy in HIV-infected adults. AIDS (2005) 1.37
CDC/NIH Workshop. Tuberculosis biomarker and surrogate endpoint research roadmap. Am J Respir Crit Care Med (2011) 1.37
Recombinant human growth hormone to treat HIV-associated adipose redistribution syndrome: 12 week induction and 24-week maintenance therapy. J Acquir Immune Defic Syndr (2007) 1.37
Pooled nucleic acid testing to identify antiretroviral treatment failure during HIV infection. J Acquir Immune Defic Syndr (2010) 1.36
A 96-week comparison of lopinavir-ritonavir combination therapy followed by lopinavir-ritonavir monotherapy versus efavirenz combination therapy. J Infect Dis (2008) 1.33
Episomal viral cDNAs identify a reservoir that fuels viral rebound after treatment interruption and that contributes to treatment failure. PLoS Pathog (2011) 1.32
Cross-sectional detection of acute HIV infection: timing of transmission, inflammation and antiretroviral therapy. PLoS One (2011) 1.32
Virological and pharmacological parameters predicting the response to lopinavir-ritonavir in heavily protease inhibitor-experienced patients. Antimicrob Agents Chemother (2005) 1.30
Epidemiology of neurocysticercosis in Houston, Texas. Am J Trop Med Hyg (2005) 1.30
Severe Rift Valley fever may present with a characteristic clinical syndrome. Am J Trop Med Hyg (2010) 1.29
Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV. AIDS (2007) 1.29
Treatment of cryptosporidiosis: do we know what we think we know? Curr Opin Infect Dis (2010) 1.29
Zoonotic larval cestode infections: neglected, neglected tropical diseases? PLoS Negl Trop Dis (2009) 1.26
Immune reconstitution is comparable in antiretroviral-naive subjects after 1 year of successful therapy with a nucleoside reverse-transcriptase inhibitor- or protease inhibitor-containing antiretroviral regimen. J Infect Dis (2003) 1.26
A novel calcium-dependent protein kinase inhibitor as a lead compound for treating cryptosporidiosis. J Infect Dis (2013) 1.23
Regulatory T cell expansion in HTLV-1 and strongyloidiasis co-infection is associated with reduced IL-5 responses to Strongyloides stercoralis antigen. PLoS Negl Trop Dis (2009) 1.23
Sequential outbreaks of infections by distinct Acinetobacter baumannii strains in a public teaching hospital in Houston, Texas. J Clin Microbiol (2007) 1.23
HIV and noncommunicable cardiovascular and pulmonary diseases in low- and middle-income countries in the ART era: what we know and best directions for future research. J Acquir Immune Defic Syndr (2014) 1.22
Dolutegravir for the treatment of HIV. Expert Opin Investig Drugs (2012) 1.20
Neurocysticercosis in Houston, Texas: an update. Medicine (Baltimore) (2011) 1.19
Metabolic basis of HIV-lipodystrophy syndrome. Am J Physiol Endocrinol Metab (2002) 1.18
A lopinavir/ritonavir-based once-daily regimen results in better compliance and is non-inferior to a twice-daily regimen through 96 weeks. AIDS Res Hum Retroviruses (2007) 1.18